| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 1 data readout example | Phase 1 | — | Subscribe to access the data. | Small Molecules | Oncology | ||
Phase 1 data readout example | Phase 1 | — | Subscribe to access the data. | Small Molecules | Oncology | ||
Phase 1 data readout example | Phase 1 | — | Subscribe to access the data. | Small Molecules | Oncology |
Recent Updates
Recently added Catalysts
Erasca, Inc.$18.53
-0.78 (-4.07%)
C 53Pipeline Score Overvalued Pharma · Clinical
Market Cap
3.50 B
EPS
-0.93
P/E Ratio
-
Value Trade
60.45 M
SEC Financials
Q1 2026Dilution Risk
R&D Expenses
27.27 M
Operating CF
-27.38 M
Total Assets
461.23 M
Total Liabilities
67.71 M
Equity
393.53 M
D/E Ratio
12,345
10.63 %
Week
-50.29 %
1 Month
-9.21 %
3 Month
304.32 %
6 Month
-29.31 %
5 Year
-29.31 %
All Time
Cash Data
Cash Position
243.79 M
Monthly Burn
9.13 M
Runway
24.9 mo
Burn Trend
StableSEC Filing
May 11, 2026
Overview
Volume
3.02 M
52 Week Range
1.06 - 24.28
% held by Insiders
39.85 %
% held by Institutions
63.43 %
Enterprise Value
3.30 B
Total Shares
283.79 M
Short %
14.71 %
Float Shares
219.65 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Erasca, Inc.
328Total events
5Upcoming
80Tier-1 (high impact)
2020 – 2027Coverage
Upcoming catalysts 5
Event history 323
Q3 2026
◆Topline ReadoutERAS-4001Clinical Data
Initial Phase 1 monotherapy data for ERAS-4001 expected in 2H 2026
KRAS-mutant solid tumorssource ↗
Jun 18, 2026
▼IP Litigation RulingERAS-0015IP / Competition
Securities class action lawsuit filed against Erasca for alleged false statements regarding ERAS-0015
RAS-mutated solid tumorssource ↗
Jun 3, 2026
◆Oral PresentationPresentation
Erasca management to present at Jefferies Global Healthcare Conference
May 13, 2026
◆Oral PresentationPresentation
Erasca management to present at Bank of America Securities Health Care Conference
May 11, 2026
▲Partnership / LicenseERAS-0015Corporate
Clinical trial collaboration and supply agreement with Merck for ERAS-0015 + KEYTRUDA
RAS-mutant solid tumorssource ↗
May 2026
▲Partnership / LicenseERAS-0015Corporate
Clinical Trial Collaboration and Supply Agreement with Merck for ERAS-0015 + KEYTRUDA
Apr 28, 2026
▼IP Litigation RulingERAS-0015IP / Competition
Revolution Medicines alleges ERAS-0015 infringes patent and involves trade secret misappropriation
cancerssource ↗
Apr 28, 2026
◆Topline ReadoutERAS-0015Clinical Data
Preliminary Phase 1 dose-escalation data for ERAS-0015 announced
Apr 27, 2026
▼IP Litigation RulingERAS-0015IP / Competition
RevMed challenges Erasca's IP claims for ERAS-0015
RAS-mutant solid tumorssource ↗
Apr 27, 2026
▼Serious Ae Or DeathERAS-0015Safety
Patient death after ERAS-0015 treatment
RAS-mutant solid tumorssource ↗
Apr 27, 2026
◆Oral PresentationERAS-0015Presentation
Conference call and webcast to discuss preliminary Phase 1 dose escalation data for ERAS-0015
RAS-mutant solid tumorssource ↗
Drug Pipeline Intelligence
C53
Pipeline Score $1.9B
Pipeline ValueOvervalued
Valuation Signal6
Drugs Scored0.6x
rNPV / MCap Top 81%
Small Cap (rank 174 of 911)
Percentile RankErasca, Inc. carries a moderate pipeline score (53/100), with $3.0B risk-adjusted pipeline value, led by Naporafenib in Advanced or Metastatic Solid Tumors (Phase 1).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Naporafenib Small molecule | Advanced or Metastatic NRAS-mutant Melanoma | Phase 3 | NCT06346067 | 42% | $941M | ACTIVE NOT_RECRUITING | 78 | SLOW | C (57) | Dec 1, 2028 | ELEVATED_RISK | LOW May 26, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
ERAS-0015 | KRAS G12X non-small cell lung cancer and pancreatic ductal adenocarcinoma | — | 2026-05-11 | robust response rates in KRAS G12X non-small cell lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC); mostly low-grade adverse events (AEs); limited dose reductions due to treatment-related adverse events (TRAEs); no discontinuations due to TRAEs; dose-dependent exposure with no observed plateau; recommended doses for expansion: 24 mg and 32 mg QD (once daily) Read More | Erasca Reports First Quarter 2026 Business Updates and Financial Results Robust monotherapy efficacy and generally well-tolerated safety results observed during dose escalation for ERAS-0015 in both KRAS G12X NSCLC and P Read More | |
ERAS-0015 | KRAS G12X non-small cell lung cancer and pancreatic ductal adenocarcinoma | — | 2026-05-11 | robust response rates in KRAS G12X non-small cell lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC); mostly low-grade adverse events (AEs); limited dose reductions due to treatment-related adverse events (TRAEs); no discontinuations due to TRAEs; dose-dependent exposure with no observed plateau; recommended doses for expansion: 24 mg and 32 mg QD (once daily) Read More | Erasca Reports First Quarter 2026 Business Updates and Financial Results Robust monotherapy efficacy and generally well-tolerated safety results observed during dose escalation for ERAS-0015 in both KRAS G12X NSCLC and P Read More | |
ERAS-0015 | KRAS G12X non-small cell lung cancer and pancreatic ductal adenocarcinoma | — | 2026-05-11 | robust response rates in KRAS G12X non-small cell lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC); mostly low-grade adverse events (AEs); limited dose reductions due to treatment-related adverse events (TRAEs); no discontinuations due to TRAEs; dose-dependent exposure with no observed plateau; recommended doses for expansion: 24 mg and 32 mg QD (once daily) Read More | Erasca Reports First Quarter 2026 Business Updates and Financial Results Robust monotherapy efficacy and generally well-tolerated safety results observed during dose escalation for ERAS-0015 in both KRAS G12X NSCLC and P Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in ERAS
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
ERAS Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
ERASErasca, Inc. (ERAS) Faces Securities Class Action Amid Patient Death, Intellectual Property Questions, $2.8 Billion Market Cap Loss -- HBSS
Erasca, Inc. is facing a securities class action following a significant drop in its stock price attributed to allegations of patent infringement from Revolution Medicines. The lawsuit claims that Erasca misled investors about its investigational treatment for solid tumors, ERAS-0015, particularly after the death of a patient who received the treatment. Additionally, concerns have been raised regarding the validity of its intellectual property claims. These issues have resulted in a market capitalization loss of over $2.8 billion for the company.
Read more →ERASErasca Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Erasca - ERAS
Erasca Inc. is reminded by ClaimsFiler of the impending deadline for investors to file lead plaintiff applications in a securities class action lawsuit. The lawsuit, pending in the Southern District of California, alleges that Erasca and its executives failed to disclose significant information during the Class Period, which could mislead investors. Specific claims involve the questionable preclinical data associated with ERAS-0015, resulting in potential legal liabilities for the company.
Read more →ERAS▲ +8.4%on this news· ran to +20% by day 3
Erasca to Present at the Jefferies Global Healthcare Conference
Erasca, Inc. will participate in the Jefferies Global Healthcare Conference on June 3, 2026. The event will feature a fireside chat and one-on-one investor meetings. A live audio webcast will be available, with an archived replay for 30 days. Erasca focuses on therapies for RAS/MAPK pathway-driven cancers.
Read more →ERASERASCA INVESTOR ALERT: Bragar Eagel & Squire, P.C. is Investigating Erasca, Inc. on Behalf of Erasca Stockholders and Encourages Investors to Contact the Firm
Erasca, Inc. (NASDAQ:ERAS) is under investigation by Bragar Eagel & Squire, P.C. on behalf of stockholders following a significant drop in its share price. This decline was triggered by a letter from Revolution Medicines alleging that Erasca's ERAS-0015 infringed on a patent and involved trade secret misappropriation. Since the news broke, Erasca's stock fell from $19.15 to $9.90, a reduction of nearly 48%. Shareholders who have suffered losses are being encouraged to contact the law firm to discuss their legal rights.
Read more →ERASErasca, Inc. (ERAS) Shares Crater 48%, Wiping Out $2.8 Billion of Market Cap; Hagens Berman Investigating Intellectual Property Questions Regarding Lead Asset
Erasca, Inc. (ERAS) experienced a dramatic 48% decline in share price after revealing that its lead product candidate, ERAS-0015, is facing legal challenges regarding intellectual property from competitor Revolution Medicines. As a result, Hagens Berman has launched an investigation into whether Erasca may have misled investors about the viability of its intellectual property. The company's assurances regarding ERAS-0015's competitive advantages and protections are now under scrutiny following a serious legal complaint from Revolution Medicines.
Read more →ERASErasca Announces Clinical Trial Collaboration and Supply Agreement with Merck to Evaluate ERAS-0015 in Combination with KEYTRUDA® (Pembrolizumab)
Erasca, Inc. has announced a collaboration with Merck to evaluate ERAS-0015 in combination with KEYTRUDA for treating RAS-mutant solid tumors. The AURORAS-1 trial aims to assess the effectiveness of this combination therapy. Early data from the trial indicates promising safety and tolerability, with potential benefits in overcoming treatment resistance.
Read more →ERASErasca Reports First Quarter 2026 Business Updates and Financial Results Robust monotherapy efficacy and generally well-tolerated safety results observed during dose escalation for ERAS-0015 in both KRAS G12X NSCLC and P
Erasca, Inc. provided a detailed update on its business and financial results for Q1 2026. The company reported promising results for its lead candidate ERAS-0015, showing robust efficacy and safety in treating KRAS G12X non-small cell lung cancer and pancreatic cancer. A significant cash balance supports ongoing operations into 2028. Erasca entered collaborations with Merck and Tango Therapeutics to explore combination therapies. Despite a substantial net loss for the quarter, the advancements in their clinical pipeline suggest a strong potential in the oncology market.
Read more →ERAS▲ +9.1%on this newsshared move
Erasca to Present at the Bank of America Securities Health Care Conference
Erasca, Inc. (Nasdaq: ERAS) is set to present at the 2026 Bank of America Securities Health Care Conference in Las Vegas on May 13, 2026. The event will feature a fireside chat followed by one-on-one investor meetings. A live audio webcast and an archived replay will be accessible on the company's website. Erasca focuses on therapies for RAS/MAPK pathway-driven cancers, emphasizing its commitment to erasing cancer.
Read more →ERASErasca, Inc. Investors Should Contact Block & Leviton LLP to Learn More About Securities Fraud Investigation
Erasca, Inc. is currently under investigation by Block & Leviton for possible securities law violations. This follows a significant decline in its stock price, which dropped over 45% after allegations of patent infringement and trade secret misappropriation surfaced. Investors who have experienced losses are being encouraged to contact Block & Leviton to explore recovery options. The situation may lead to legal actions that could further impact Erasca's stability in the market.
Read more →ERAS▼ -48.3%on this news
Erasca Announces Positive Preliminary Phase 1 Dose Escalation Data for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid Tumors
Erasca, Inc. announced positive preliminary Phase 1 data for its pan-RAS molecular glue, ERAS-0015, showing robust efficacy in KRAS-mutant solid tumors, particularly in non-small cell lung cancer and pancreatic cancer. The treatment demonstrated high overall response rates and was generally well-tolerated. The company anticipates further data disclosures in 2027, indicating strong potential for ERAS-0015 as a backbone therapy in future regimens.
Read more →ERAS▼ -48.3%on this newsshared move
Erasca, Inc. Investigated For Securities Fraud; Block & Leviton Encourages Investors to Contact the Firm to Possibly Recover Losses
Block & Leviton is investigating Erasca, Inc. for potential securities law violations after the company disclosed that it received a letter from Revolution Medicines alleging patent infringement related to its asset, ERAS-0015. This news coincided with a significant drop of over 45% in Erasca's stock price during premarket trading. Investors who have incurred losses are encouraged to reach out to Block & Leviton for more information on recovery options. The firm has a history of representing investors in similar cases.
Read more →ERAS▼ -48.3%on this newsshared move
Erasca, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
Erasca, Inc. is facing scrutiny from Johnson Fistel, PLLP regarding potential legal claims related to investor losses under federal securities laws. This comes after Erasca disclosed receiving a letter from Revolution Medicines, Inc. alleging improper comparisons of preclinical data between ERAS-0015 and RMC-6236. Despite Erasca's assertion that the claims are baseless and their intention to contest, the investigation may further impact the company's share price and investor confidence. Johnson Fistel encourages affected shareholders to reach out for potential recovery options.
Read more →ERAS▼ -10.9%on this news· ran to -54% by day 1shared move
Erasca to Host Conference Call and Webcast to Discuss Preliminary Phase 1 Dose Escalation Data for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015
Erasca, Inc. announced a conference call to discuss preliminary Phase 1 dose escalation data for ERAS-0015, a pan-RAS molecular glue. The data indicates favorable safety and tolerability, with partial responses in patients with RAS-mutant solid tumors. The call is scheduled for April 27, 2026, at 4:30 pm ET.
Read more →ERAS▼ -7%on this news
Erasca Reports Fourth Quarter and Full Year 2025 Business Updates and Financial Results
Erasca, Inc. reported positive updates for the fourth quarter and full year 2025, highlighting early clinical activity with ERAS-0015 and a successful $259 million financing. The company anticipates further data from its clinical trials in 2026, with a strong cash position expected to sustain operations into late 2028. Despite a net loss of $124.5 million, the outlook remains optimistic due to ongoing responses in RAS-mutant tumors.
Read more →ERASErasca Exercises Option to Secure Worldwide Rights for ERAS-0015 Pan-RAS Molecular Glue to Include China, Hong Kong, and Macau
Erasca, Inc. has exercised its option to expand its license agreement with Joyo Pharmatech, securing worldwide rights for its pan-RAS molecular glue, ERAS-0015, specifically including China, Hong Kong, and Macau. This expansion allows Erasca to pursue a unified global development strategy. The early clinical data for ERAS-0015 indicates its potential as a best-in-class RAS-targeting agent, with initial Phase 1 monotherapy data expected by the first half of 2026. The company remains optimistic based on promising early results across various tumor types and RAS mutations.
Read more →ERASErasca and Tango Therapeutics Enter into Clinical Collaboration to Evaluate Combination of ERAS-0015 and Vopimetostat
Erasca has announced a clinical collaboration with Tango Therapeutics to evaluate ERAS-0015, a pan-RAS molecular glue, in combination with Tango's PRMT5 inhibitor, vopimetostat. This Phase 1/2 trial will focus on patients with MTAP-deleted pancreatic and non-small cell lung cancers. The collaboration aims to enhance treatment options for these patients, who currently have limited therapies available.
Read more →ERASErasca Announces Issuance of a U.S. Patent Covering Pan-KRAS Inhibitor ERAS-4001
Erasca, Inc. announced the issuance of a U.S. patent for its pan-KRAS inhibitor ERAS-4001, providing protection until at least 2043. This patent enhances Erasca's intellectual property portfolio and supports the development of its RAS-driven cancer therapies. Initial Phase 1 data for ERAS-4001 is expected in the second half of 2026.
Read more →ERAS▲ +5.7%on this news
Erasca to Present at Upcoming Conferences in February
Erasca, Inc. announced its participation in two key investor conferences in February 2026. The company will engage in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit and the Oppenheimer 36th Annual Healthcare Life Sciences Conference. These events highlight Erasca's commitment to advancing therapies for RAS/MAPK pathway-driven cancers.
Read more →ERASErasca Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
Erasca, Inc. has successfully closed an upsized public offering of 25,875,000 shares of common stock, generating approximately $258.8 million in gross proceeds. The funds will be used to support the development of its cancer therapies and for general corporate purposes. The offering was managed by several prominent financial institutions.
Read more →ERASErasca Announces Pricing of Upsized Public Offering of Common Stock
Erasca, Inc. has announced the pricing of an upsized public offering of 22,500,000 shares of its common stock at $10.00 per share, aiming to raise $225 million. The funds raised will be utilized to support research and development initiatives as well as general corporate purposes. This offering, expected to close on January 23, 2026, follows a previously declared effective shelf registration statement. J.P. Morgan, Morgan Stanley, Jefferies, and Evercore ISI are the joint underwriters managing the offering.
Read more →ERASErasca Announces Proposed Public Offering of $150 Million of Common Stock
Erasca, Inc. announced a proposed public offering of $150 million in common stock to fund research and development for therapies targeting RAS/MAPK pathway-driven cancers. The company plans to grant underwriters a 30-day option for an additional $22.5 million. The offering is subject to market conditions and may not be completed as planned.
Read more →ERAS▼ -7.8%on this news· ran to +41% by day 3
We caution you that this presentation contains forward-looking statements. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of ope
Erasca has presented a forward-looking corporate overview detailing their mission to innovate cancer therapies targeting the RAS/MAPK pathway. Their pipeline includes prominent candidates ERAS-0015 and ERAS-4001, aimed at addressing oncogenic mutations. The company boasts a strong cash position and a seasoned leadership team, yet acknowledges various risks associated with clinical trial outcomes and market conditions. Caution is advised, as potential results may vary from expectations due to inherent uncertainties in the development process.
Read more →ERAS▼ -7.8%on this news· ran to +41% by day 3
Erasca Announces Promising Early Clinical Data for ERAS-0015 and 2026-2027 Milestones
Erasca announced encouraging early clinical data for ERAS-0015, a potential best-in-class pan-RAS molecular glue, demonstrating confirmed partial responses in various tumor types with different RAS mutations. The company outlined its upcoming milestones, with plans for initial Phase 1 monotherapy data expected in the first half of 2026. Early results indicate favorable safety and tolerability, as well as positive pharmacokinetics, further supporting the drug's clinical progression. Additionally, ERAS-4001, a potential first-in-class pan-KRAS inhibitor, is advancing in its trials with similar expectations for early data.
Read more →ERASErasca to Present at the 44th Annual J.P. Morgan Healthcare Conference
Erasca, Inc. (Nasdaq: ERAS), a precision oncology company, announced its participation in the 44th Annual J.P. Morgan Healthcare Conference in San Francisco. Management will present on January 13, 2026, and will also engage in one-on-one meetings with investors. The company focuses on targeting cancers related to the RAS/MAPK pathway, with the goal of discovering and commercializing effective therapies for affected patients.
Read more →ERAS▲ +6.2%on this news
Erasca to Present at the 8th Annual Evercore Healthcare Conference
Erasca, Inc. (Nasdaq: ERAS), a precision oncology company, will present at the 8th Annual Evercore Healthcare Conference on December 3, 2025. The event will take place at the Loews Coral Gables Hotel in Florida, where Erasca’s management is expected to participate in a fireside chat and one-on-one investor meetings. A live webcast of the event will be available, showcasing the company's efforts to develop therapies targeting RAS/MAPK pathway-driven cancers.
Read more →ERASErasca Reports Third Quarter 2025 Business Updates and Financial Results
Erasca, Inc. reported its third quarter 2025 business updates, highlighting the issuance of a U.S. patent for its pan-RAS molecular glue ERAS-0015. The company promoted Robert Shoemaker to chief scientific officer and anticipates initial Phase 1 data for ERAS-0015 and ERAS-4001 in 2026. Despite a strong cash position of $362 million, Erasca reported a net loss of $30.6 million for the quarter.
Read more →ERASErasca Announces Issuance of a U.S. Patent Covering Pan-RAS Molecular Glue ERAS-0015
Erasca, Inc. announced the issuance of a U.S. patent for its pan-RAS molecular glue ERAS-0015, providing protection until at least 2043. This patent is a significant milestone for the company, which is focused on therapies for RAS/MAPK pathway-driven cancers. Initial Phase 1 data for ERAS-0015 and the pan-KRAS inhibitor ERAS-4001 is anticipated in 2026.
Read more →ERASErasca to Present at Upcoming Conferences in November
Erasca, Inc. announced its participation in several investor conferences in November 2025, including the Guggenheim 2nd Annual Healthcare Innovation Conference, Stifel 2025 Healthcare Conference, and Jefferies Global Healthcare Conference. The company will engage in fireside chats and one-on-one meetings to discuss its focus on RAS/MAPK pathway-driven cancers. Live audio webcasts of the events will be available on their website.
Read more →ERASErasca to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference
Erasca, Inc. will present at the Morgan Stanley 23rd Annual Global Healthcare Conference on September 9, 2025. The event will take place at the Sheraton New York Times Square, where management will discuss their work in precision oncology and participate in investor meetings. A live audio webcast will be available for those unable to attend in person.
Read more →ERAS▲ +5.4%on this news
Erasca Reports Second Quarter 2025 Business Updates and Financial Results
Erasca, Inc. reported its business updates and financial results for Q2 2025, highlighting the advancement of its RAS-targeting franchise with promising Phase 1 trials expected in 2026 for its therapies ERAS-0015 and ERAS-4001. As of June 30, 2025, the company holds a healthy cash position of $387 million, which is projected to fund operations into late 2028. However, a net loss of $33.9 million was recorded for the quarter, showcasing the financial challenges faced. The company continues to pursue innovative treatments for patients with RAS-driven tumors amidst inherent development risks.
Read more →ERAS▲ +5.4%on this news
Erasca, Inc. Condensed Consolidated Statements of Operations and Comprehensive Loss (In thousands, except share and per share amounts) (Unaudited) Three Months Ended June 30, Six Months Ended
Erasca, Inc. has reported its second quarter 2025 business updates and financial results, highlighting progress in its RAS-targeting therapies ERAS-0015 and ERAS-4001 with expected Phase 1 data in 2026. The company has Rs 387 million in cash and marketable securities, sufficient to support operations through late 2028. However, Erasca also recorded substantial net losses and a decline in cash reserves compared to the previous year. The company emphasizes cautious optimism as it moves forward with its clinical trials amidst inherent development risks.
Read more →ERASErasca Announces IND Clearance for Potential First-in-Class and Best-in-Class Pan-KRAS Inhibitor ERAS-4001
Erasca, Inc. announced that the FDA has granted IND clearance for ERAS-4001, a potential first-in-class pan-KRAS inhibitor aimed at treating KRAS-mutant solid tumors. The company plans to advance both ERAS-4001 and ERAS-0015 into clinical trials, with initial Phase 1 data expected in 2026. The BOREALIS-1 trial will assess the safety and efficacy of ERAS-4001, while ERAS-0015 is being evaluated in the AURORAS-1 trial.
Read more →ERAS▲ +31.8%on this newsshared move
Erasca to Present at Upcoming Investor Conferences in June
Erasca, Inc. will present at two major investor conferences in June 2025, including the Jefferies Global Healthcare Conference and the Goldman Sachs 46th Annual Global Healthcare Conference. Management will also hold one-on-one meetings at these events. The company is dedicated to developing therapies for RAS/MAPK pathway-driven cancers.
Read more →ERASErasca Announces Early Clinical Advancement and Prioritization of RAS-Targeting Franchise Coupled with More than 3 Years of Projected Cash Runway
Erasca, Inc. announced the FDA's clearance of an IND for ERAS-0015 and the submission of an IND for ERAS-4001, both targeting RAS mutations in solid tumors. The company also revealed a strategic shift to seek partnerships for naporafenib, extending its cash runway guidance to 2028. Phase 1 trial data for both programs is anticipated in 2026.
Read more →ERASErasca Reports First Quarter 2025 Business Updates and Financial Results Early entry of RAS-targeting franchise into clinic enabled by strong execution Initial Phase 1 monotherapy data for pan-RAS molecular glue ERAS-001
Erasca, Inc. has reported significant advancements in its RAS-targeting franchise, with the recent clearance for the IND of ERAS-0015 and the submission of IND for ERAS-4001, indicating a promising entry into clinical trials. The company, focused on RAS/MAPK pathway-driven cancers, boasts a robust cash position of $411 million, allowing for sustained operations through 2028. Initial monotherapy data for both candidates is anticipated in 2026, underscoring the company's commitment to addressing unmet needs in oncology.
Read more →ERASErasca Presents New Preclinical Data Reinforcing Best-in-Class Potential of RAS-Targeting Franchise at the 2025 AACR Annual Meeting
Erasca, Inc. presented new preclinical data at the 2025 AACR Annual Meeting, emphasizing the potential of their RAS-targeting franchise. Key highlights include the robust anti-tumor activity of ERAS-0015 and ERAS-4001, both showcasing best-in-class properties in their respective categories. These compounds demonstrated strong pharmacokinetic profiles and effectiveness across various cancer models, bolstering Erasca's commitment to targeting RAS/MAPK pathway-driven cancers. The company is positioned to advance both compounds into clinical development within the year.
Read more →ERASErasca Announces Three Poster Presentations at the 2025 AACR Annual Meeting
Erasca, Inc. has announced three poster presentations at the 2025 AACR Annual Meeting, showcasing advancements in their cancer treatment pipeline. The presentations will include details on ERAS-0015, a pan-RAS molecular glue, and ERAS-4001, a pan-KRAS inhibitor, as well as innovative direct SMP complex inhibitors targeting the RAS/MAPK pathway. These developments reflect Erasca's commitment to advancing precision oncology, though they also come with certain risks and challenges inherent in drug development and clinical trials.
Read more →ERASErasca Reports Fourth Quarter and Full Year 2024 Business Updates and Financial Results Potentially best-in-class RAS-targeting franchise advancing with both ERAS-0015 and ERAS-4001 expected to enter the clinic in 2025 O
Erasca, Inc. has reported its fourth quarter and full year 2024 business updates, highlighting advancements in its RAS-targeting drug candidates ERAS-0015 and ERAS-4001 that are set to enter clinical trials in 2025. The company maintains a robust financial position with $440 million in cash, expected to fund operations into late 2027. The SEACRAFT-2 trial is underway with randomized data anticipated in H2 2025, and significant enthusiasm surrounds the potential first-to-market status in NRASm melanoma due to the lack of existing targeted therapies. However, rising R&D expenses and the uncertain nature of clinical trials pose potential challenges ahead.
Read more →ERASErasca to Present at the Guggenheim Securities SMID Cap Biotech Conference
Erasca, Inc. announced its participation in the Guggenheim Securities SMID Cap Biotech Conference scheduled for February 6, 2025. The company will engage in a fireside chat as well as one-on-one meetings with investors at the event. This conference offers a platform for Erasca to showcase its dedication to developing precision oncology therapies targeting RAS/MAPK pathway-driven cancers. A live audio webcast and subsequent archive will be available on their website.
Read more →ERASErasca to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Erasca, Inc. is set to present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14, 2025, in San Francisco, California. The company's focus is on developing therapies specifically for RAS/MAPK pathway-driven cancers. This engagement highlights their commitment to innovation in precision oncology. Additionally, they will offer a live audio webcast of their presentation, further increasing transparency with investors.
Read more →ERASErasca Reports Third Quarter 2024 Business Updates and Financial Results Positive preliminary Phase 1b data in SEACRAFT-1 NRASm melanoma cohort bolsters conviction in ongoing SEACRAFT-2 registrational trial; Stage 1 rand
Erasca, Inc. reported positive developments for Q3 2024, highlighted by promising preliminary data from the SEACRAFT-1 trial that increases confidence in its SEACRAFT-2 registrational trial focusing on NRASm melanoma. The company is well-capitalized with a robust cash position of $463 million, expected to extend its operational runway into the first half of 2027. Ongoing developments include planned IND submissions for innovative products ERAS-0015 and ERAS-4001, alongside anticipated data from pivotal trials expected in 2025. However, the increase in net loss and dependency on trial successes present challenges.
Read more →ERASErasca to Present at Upcoming Investor Conferences
Erasca, Inc., a clinical-stage precision oncology company, is set to present at several investor conferences in November and December 2024. Management will participate in a fireside chat at the Guggenheim Securities Healthcare Innovation Conference and other significant events in London and Florida. These conferences aim to highlight Erasca's work in developing therapies for RAS/MAPK pathway-driven cancers, reflecting its ongoing commitment to cancer treatment innovations.
Read more →ERASErasca Announces Strong Momentum for Naporafenib and RAS Targeting Franchise
Erasca, Inc. has reported strong progress in its clinical trials for naporafenib and its RAS targeting franchise. Positive data from the SEACRAFT-1 trial indicates the drug's potential in treating NRASm melanoma, leading to regulatory alignment for the Phase 3 SEACRAFT-2 trial, with results expected in 2025. The company's strategic focus on developing novel therapies for RAS/MAPK pathway-driven cancers is reflected in its ongoing projects, including the advancement of its investigational new drug applications for two promising compounds.
Read more →ERAS▲ +8.1%on this news
Erasca to Present Preliminary SEACRAFT-1 Phase 1 Data for Naporafenib Plus Trametinib in RAS Q61X Mutant Solid Tumors as Oral Presentation at 36th EORTC-NCI-AACR Symposium
Erasca, Inc. announced its intention to present preliminary data from the SEACRAFT-1 Phase 1 trial focusing on naporafenib plus trametinib for treating locally advanced solid tumors with RAS Q61X mutations. This presentation will take place at the 36th EORTC-NCI-AACR Symposium in Barcelona on October 24, 2024. Naporafenib is positioned as a first-in-class pan-RAF inhibitor, and Erasca is also conducting a pivotal Phase 3 trial, SEACRAFT-2, in NRAS-mutant melanoma, showing previously favorable survival data. A virtual investor event will be held alongside the symposium for further updates on the therapy's development.
Read more →ERASErasca to Present at Upcoming Investor Conferences in September
Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology firm, has announced its participation in major investor conferences in September 2024, including the Morgan Stanley Global Healthcare Conference and the Cantor Global Healthcare Conference. During these events, management will engage with investors, showcasing their commitment to addressing RAS/MAPK pathway-driven cancers. The company emphasizes its mission to develop innovative therapies designed to combat cancer effectively. Webcasts of the presentations will be available for public access via their website.
Read more →ERAS▲ +7.9%on this news
Erasca Reports Second Quarter 2024 Business Updates and Financial Results In-licensed potential best-in-class pan-RAS molecular glue ERAS-0015 and potential first-in-class pan-KRAS inhibitor ERAS-4001 with a goal of expa
Erasca, Inc. has shared significant developments in its second quarter of 2024, including the in-licensing of two promising therapies aimed at treating RAS-driven tumors. The company initiated the SEACRAFT-2 Phase 3 trial for naporafenib and trametinib in NRASm melanoma patients. With a cash reserve of $460 million, Erasca is well-funded to continue its research and development through mid-2027. However, the financial report shows a net loss of $63.2 million, highlighting the ongoing challenges faced by the company in achieving profitability.
Read more →ERASErasca Initiates SEACRAFT-2 Pivotal Phase 3 Trial Evaluating Naporafenib Plus Trametinib in Patients with NRAS-Mutant Melanoma
Erasca, Inc. has launched the global SEACRAFT-2 Phase 3 trial to evaluate the efficacy of naporafenib combined with trametinib in patients with NRAS-mutant melanoma. This pivotal trial aims to address the high unmet medical need for targeted therapies in this aggressive cancer type. Preliminary analyses of earlier trials show favorable survival rates with the combination therapy. Regulatory approval processes have been integrated into the trial's design to bolster its credibility.
Read more →ERASErasca Announces Closing of Underwritten Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
Erasca, Inc. has successfully closed an oversubscribed underwritten offering of 99,459,458 shares of its common stock, raising around $184.0 million. The offering included a full exercise of the underwriters' option to purchase additional shares at a price of $1.85 each. Proceeds will be utilized for funding research and development of product candidates, working capital, and general corporate purposes. J.P. Morgan and BofA Securities acted as joint book-running managers for the offering.
Read more →ERAS▲ +6.5%on this news· ran to +32% by day 3shared move
Erasca Announces Strategic In-Licensing of RAS-Targeting Franchise
Erasca, Inc. has announced the in-licensing of two promising RAS-targeting therapies, ERAS-0015 and ERAS-4001, aimed at addressing unmet medical needs for patients with RAS-mutant tumors. These compounds are expected to provide strong potential efficacy profiles based on encouraging preclinical data. Concurrently, the company is undergoing a workforce restructuring, leading to an approximate 18% reduction in staff, focusing efforts on programs with the highest probability of success. This strategic pivot aims to enhance Erasca's capabilities in oncology treatment while dealing with the inherent challenges of shifting resources.
Read more →ERASOn a Journey to Erase Cancer Erasca Investor Update May 2024 Disclaimer: Forward Looking Statements & Market Data We caution you that this presentation contains forward-looking statements. All statements other than state
Erasca provided an investor update outlining its mission to target the RAS/MAPK pathway in oncology, aiming to potentially benefit 100,000 cancer patients annually. The company highlighted a strong financial posture with $334 million in cash and a pipeline featuring candidates like ERAS-0015 and ERAS-4001. However, the update also raised concerns about the reliance on forward-looking statements and the risks associated with a limited product pipeline and potential trial delays.
Read more →ERASErasca Announces Pricing of Underwritten Offering of Common Stock
Erasca, Inc. has announced the pricing of an underwritten offering of 86,486,486 shares of its common stock at $1.85 per share, expected to raise approximately $160 million. The offering is aimed at funding research and development for therapies targeting RAS/MAPK pathway-driven cancers. Closing is anticipated on May 21, 2024, contingent on customary conditions. The company possesses a robust pipeline in the oncology sector, emphasizing its commitment to addressing cancer treatment.
Read more →ERASErasca Reports First Quarter 2024 Business Updates and Financial Results Median OS of 13-14 months for naporafenib plus trametinib in pooled analysis of patients with NRASm melanoma Strengthened balance sheet with privat
Erasca, Inc. has announced its first quarter 2024 business updates, highlighting significant findings from a pooled analysis demonstrating improved median overall survival in NRASm melanoma patients treated with naporafenib and trametinib. The company has successfully secured $45 million in private investment, allowing it to extend its funding into the latter half of 2026. Additionally, Erasca is poised to initiate several pivotal clinical trials in the near future, although it reported a net loss of $35 million for the quarter, marking a rise from the previous year. The company is focused on expanding treatment options against RAS/MAPK driven cancers through its pipeline of therapies.
Read more →ERASErasca to Present at the Bank of America Health Care Conference
Erasca, Inc. announced its participation in the Bank of America Health Care Conference scheduled for May 15, 2024, in Las Vegas, Nevada. The clinical-stage precision oncology company focuses on therapies for RAS/MAPK pathway-driven cancers. Management will present at the conference and participate in one-on-one investor meetings, enhancing their visibility and engagement within the healthcare sector. The event will be available for streaming online, indicating transparency in their communications.
Read more →ERASErasca Announces Three Presentations at the 2024 ASCO Annual Meeting
Erasca, Inc. (NASDAQ: ERAS) will present new findings at the 2024 ASCO Annual Meeting, including an oral presentation of the updated HERKULES-3 results for its ERK1/2 inhibitor ERAS-007 in colorectal cancer. Additionally, two poster presentations will showcase trial designs and preliminary results pertaining to other compounds aimed at specific cancer mutations. The presentations, scheduled for June 1-3 in Chicago, aim to enhance understanding of the company’s innovative oncology therapies targeting the RAS/MAPK pathway.
Read more →ERASErasca Reports Fourth Quarter 2023 and Full Year 2023 Business Updates and Financial Results
Erasca, Inc. has reported significant business updates and financial results for Q4 and full year 2023. Achievements include gaining global registrational clarity for naporafenib, and the expected initiation of a pivotal trial (SEACRAFT-2) in 2024. The company has a robust cash position of $322 million, though it reported a net loss of $29.7 million in Q4 2023. Upcoming milestones include several critical clinical data readouts across its pipeline candidates, including ERAS-007 and ERAS-801.
Read more →ERASErasca, Inc. Consolidated Statements of Operations and Comprehensive Loss (In thousands, except share and per share amounts) (Unaudited) Three months ended December 31, Year ended
Erasca, Inc. provided significant updates for Q4 and full-year 2023, highlighting major milestones in their clinical pipeline. The company gained regulatory clarity for naporafenib, initiated key trials including SEACRAFT-2, and reported promising preliminary clinical data for ERAS-007 and ERAS-801. Their financial standing remains strong with a cash position of $322 million as of December 31, 2023, alongside a net loss reduction compared to the previous year. Multiple data readouts and clinical trials are anticipated in 2024, underscoring the company's evolving therapeutic landscape.
Read more →ERASErasca Announces $45 Million Oversubscribed Private Placement Financing Funding from new and existing investors extends anticipated cash runway into H2 2026
Erasca, Inc. announced a successful oversubscribed private placement financing of $45 million from institutional accredited investors. The financing, which will close on or about April 2, 2024, is expected to enhance the company's cash runway into the second half of 2026. Funding will support the development of Erasca's RAS/MAPK pathway-driven cancer therapies and facilitate key clinical data readouts in the coming years. This initiative reflects strong investor interest in Erasca's pipeline advancements.
Read more →ERASErasca Announces Two Clinical Trial Collaboration and Supply Agreements for Trametinib to Evaluate Naporafenib Combination in SEACRAFT-1 and SEACRAFT-2 Trials
Erasca, Inc. has announced collaboration and supply agreements with Novartis for trametinib, aimed at enhancing the clinical evaluation of their pan-RAF inhibitor, naporafenib, in upcoming SEACRAFT trials. The pivotal Phase 3 SEACRAFT-2 trial targeting NRAS-mutant melanoma will initiate in the first half of 2024, while data from the Phase 1b SEACRAFT-1 trial is expected between Q2 and Q4 of the same year. These trials address significant unmet needs in RAS Q61X solid tumors and NRAS-mutant melanoma, both of which currently lack approved treatments. The agreements present promising prospects for advancing these therapeutic candidates in the oncology landscape.
Read more →ERASErasca to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
Erasca, Inc. has announced its participation in the 6th Annual Guggenheim Biotechnology Conference, scheduled for February 8, 2024, in New York City. The company's CEO, Jonathan E. Lim, M.D., along with CFO David M. Chacko, will take part in a fireside chat and one-on-one investor meetings. A live audio webcast of the event will be available on their website, enabling broader access for stakeholders. Erasca is dedicated to developing therapies targeting RAS/MAPK pathway-driven cancers, positioning itself as a specialized player in precision oncology.
Read more →ERASErasca to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Erasca, Inc. has announced its participation in the 42nd Annual J.P. Morgan Healthcare Conference. CEO Jonathan E. Lim will present an overview of the company on January 9, 2024, in San Francisco. Discussions will also include one-on-one meetings with investors. Erasca is focused on developing therapies for patients with RAS/MAPK pathway-driven cancers, emphasizing its strong pipeline and expert advisory board.
Read more →ERASErasca Granted FDA Fast Track Designation for Pan-RAF Inhibitor Naporafenib in Patients with Advanced NRAS-Mutated Melanoma
Erasca, Inc. announced that its pan-RAF inhibitor naporafenib has received FDA Fast Track Designation for the treatment of NRAS-mutated melanoma. This designation facilitates the development and review of drugs that address significant unmet medical needs. The drug has been tested on over 500 patients, showing safety and tolerability, and is set to enter a pivotal Phase 3 trial by mid-2024. However, challenges remain, including the absence of currently approved therapies for NRAS mutations and the inherent uncertainties in the drug approval process.
Read more →ERAS▼ -11.4%on this news· ran to -25% by day 3
Erasca Achieves Key Milestones for Naporafenib and ERAS-801 Programs and Extends Cash Runway
Erasca, Inc. has announced significant progress in its clinical programs for naporafenib and ERAS-801, having aligned with health authorities on the SEACRAFT-2 trial design. The company has identified the maximum tolerated dose for ERAS-801, which is set to support further patient enrollment in ongoing trials. Additionally, Erasca has extended its cash runway to the first half of 2026 through strategic prioritization of projects. While some programs have been deprioritized, the company is focusing on those with potential for high therapeutic benefits.
Read more →ERAS▼ -8.6%on this news
DATED NOVEMBER 9, 2023 EX-99 Erasca Reports Third Quarter 2023 Financial Results and Business Updates First patient dosed in SEACRAFT-1 Phase 1b trial evaluating naporafenib plus trametinib Multiple upcomin
Erasca, Inc. has reported its financial results for Q3 2023, highlighting key developments in its clinical pipeline. The company announced that the first patient was dosed in the SEACRAFT-1 Phase 1b trial for naporafenib in combination with trametinib, underscoring its ongoing commitment to oncology research. With a current cash position of $344 million, Erasca anticipates funding its operations through the second half of 2025. Upcoming data readouts from multiple clinical trials are expected between late 2023 and 2024.
Read more →ERAS▼ -8.6%on this news
Erasca Reports Third Quarter 2023 Financial Results and Business Updates
Erasca, Inc. reported its financial results for Q3 2023, highlighting the dosing of the first patient in its SEACRAFT-1 Phase 1b trial. The company has a robust cash position of $344 million, enabling ongoing clinical development. Several key milestones are expected in 2024, including data readouts from multiple trials. However, they also reported a net loss of $30.4 million and warned of potential delays in clinical operations.
Read more →ERASErasca to Present at Upcoming Investor Conferences in November
Erasca, Inc. (Nasdaq: ERAS) announced its upcoming participation in two investor conferences in November 2023, including the Jefferies London Healthcare Conference and the Evercore ISI HealthCONx Conference. These events will feature management in fireside chats, highlighting the company's focus on precision oncology for RAS/MAPK pathway-driven cancers. Erasca aims to advance its portfolio and strengthen investor relations through these engagements. The company touts a robust pipeline and expert advisory team, enhancing its mission to develop novel cancer therapies.
Read more →ERASErasca to Present at the Cantor Global Healthcare Conference
Erasca, Inc. (Nasdaq: ERAS) announced that it will participate in the Cantor Global Healthcare Conference on September 26, 2023. The event will include a fireside chat and one-on-one investor meetings. Erasca, a clinical-stage precision oncology company, focuses on developing therapies for RAS/MAPK pathway-driven cancers and believes it has a leading pipeline in this area. A live webcast of the presentation will be available on the company's website, with an archived replay accessible for 30 days following the event.
Read more →ERASErasca to Present at the Morgan Stanley 21st Annual Global Healthcare Conference
Erasca, Inc. has announced its participation at the upcoming Morgan Stanley 21st Annual Global Healthcare Conference on September 12, 2023. The event will include a fireside chat and one-on-one investor meetings, showcasing the company’s commitment to engaging with potential investors. Erasca specializes in developing therapies targeting RAS/MAPK pathway-driven cancers and aims to lead in this niche market.
Read more →ERASErasca Doses First Patient in SEACRAFT-1 Phase 1b Trial Evaluating Naporafenib Plus Trametinib in Patients with RAS Q61X Solid Tumors
Erasca, Inc. announced that it has dosed the first patient in the SEACRAFT-1 Phase 1b trial, which evaluates the combination of naporafenib and trametinib in patients with RAS Q61X solid tumors. The trial aims to explore the safety and preliminary efficacy of this treatment modality, building on prior positive results observed in related cancers. Initial data from this trial is anticipated between Q2 and Q4 of 2024, alongside the upcoming SEACRAFT-2 pivotal trial expected to start in H1 2024. This marks a significant step forward in Erasca's mission to discover and develop targeted therapies for oncology patients.
Read more →ERASErasca Reports Second Quarter 2023 Financial Results and Business Updates Significant progress across all clinical programs including Phase 1b combo data for ERAS-007 and ERAS-601, FTD and ODD granted for ERAS-801, and p
Erasca, Inc. reported its Q2 2023 financial results, highlighting significant advancements across its clinical programs. The company is focusing on therapies targeting oncogenic RAS/MAPK pathway-driven cancers and has reported promising early data for ERAS-007 and ERAS-601. Additionally, ERAS-801 has received FDA Fast Track and Orphan Drug Designations for the treatment of malignant glioma. Despite a net loss of $31.8 million for the quarter, Erasca maintains a robust cash position expected to support operations into mid-2025.
Read more →ERAS▼ -8%on this news
Erasca Granted FDA Orphan Drug Designation for CNS-Penetrant EGFR Inhibitor ERAS-801 for the Treatment of Malignant Glioma
Erasca, Inc. announced that the FDA has granted Orphan Drug Designation to ERAS-801 for the treatment of malignant glioma, including glioblastoma. ERAS-801 is characterized by its significant CNS penetration and is currently being evaluated in the ongoing THUNDERBBOLT-1 Phase 1 clinical trial, with data expected in the latter half of 2023. The designation provides benefits including assistance in drug development, tax credits, and seven years of marketing exclusivity post-approval. This recognition underscores the urgent need for novel therapies for patients with a poor prognosis.
Read more →ERAS▲ +14.2%on this news
Erasca Provides Update on Clinical Program for ERK Inhibitor ERAS-007 and Refines Pipeline
Erasca, Inc. provided an update on its clinical program for its ERK inhibitor, ERAS-007, showing promising early results with a 50% response rate in patients with metastatic BRAFm colorectal cancer. The company is prioritizing ongoing clinical trials and refining its pipeline, focusing on programs that exhibit encouraging activity. However, they have decided to deprioritize combinations that did not demonstrate adequate clinical efficacy, ensuring a more strategic approach to resource allocation. An investor event is scheduled to discuss these updates and the future of their clinical programs.
Read more →ERASErasca to Host Virtual Investor Event on Pipeline Updates with a Focus on ERAS-007 ERK Inhibitor
Erasca, Inc. has announced a virtual investor event scheduled for June 5, 2023, where the leadership team will provide updates on their pipeline, specifically highlighting ERAS-007, an ERK1/2 inhibitor in clinical development. This event aims to engage investors and share advancements in targeted therapies for RAS/MAPK pathway-driven cancers. The company's strategy focuses on innovative cancer treatments, leveraging expert insights in the field. A live Q&A session will follow the presentation, allowing direct interaction with the leadership team.
Read more →ERASErasca to Present Promising Preliminary HERKULES-3 Phase 1b Data at the 2023 ASCO Annual Meeting
Erasca, Inc. has announced promising preliminary data from the HERKULES-3 Phase 1b study evaluating the efficacy of ERAS-007 in combination with encorafenib and cetuximab for patients with metastatic BRAF V600E-mutated colorectal cancer. The combination demonstrated a response rate of 40% among evaluable patients, leading Erasca to focus on these patients for further development. However, the company will not pursue the combination of ERAS-007 and palbociclib as it did not show clinical activity in those with KRAS/NRAS mutations. The findings from the study will be presented at the upcoming ASCO Annual Meeting.
Read more →ERASErasca Further Strengthens Business Leadership with Two Key Promotions
Erasca, Inc. has announced key promotions within its executive team, elevating David Chacko, M.D., to Chief Financial Officer and Chief Business Officer, and Nik Chetwyn, Ph.D., to Chief Operating Officer. Both promotions, effective May 15, 2023, are aimed at strengthening the company's leadership as it focuses on developing therapies for RAS/MAPK pathway-driven cancers. CEO Jonathan E. Lim expressed confidence in Chacko and Chetwyn's abilities to lead Erasca through its next growth phase and potential transition to a late-stage clinical company.
Read more →ERASErasca Reports First Quarter 2023 Financial Results and Business Updates Publication of promising Phase 1b data in Journal of Clinical Oncology supports plans for pivotal Phase 3 SEACRAFT-2 trial for naporafenib in patie
Erasca, Inc. reported its first quarter 2023 financial results, revealing a net loss of $33.2 million. The company highlighted promising data from its Phase 1b trials for naporafenib, which supports the initiation of a pivotal Phase 3 SEACRAFT-2 trial expected in early 2024. Financially, Erasca maintains a robust position with approximately $390 million in cash, which is expected to fund operations into the second half of 2025. Various upcoming clinical milestones include expected data readouts from multiple trials focused on RAS-driven cancers.
Read more →ERASErasca to Present at the Bank of America Securities 2023 Health Care Conference
SAN DIEGO, May 02, 2023 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that management wil
Read more →ERASErasca Granted FDA Fast Track Designation for CNS-Penetrant EGFR Inhibitor ERAS-801 in Patients with Glioblastoma
ERAS-801 has demonstrated broad preclinical activity against oncogenic EGFR variants and wildtype alterations Initial THUNDERBBOLT-1 Phase 1 data in patients with recurrent GBM expected in H2 2023 SAN DIEGO, May 01, 2023 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinic
Read more →ERASErasca Announces Two Poster Presentations at the 2023 ASCO Annual Meeting
SAN DIEGO, April 26, 2023 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced the company will
Read more →ERASErasca Announces Publication of Promising Clinical Data Supporting the Therapeutic Potential of Naporafenib in Combination with Trametinib in NRAS-Mutant Melanoma
Promising preliminary antitumor activity with the combination demonstrated in heavily pretreated patients 47% ORR, 5.5 months mPFS observed with preferred combination dose of naporafenib 200 mg BID plus trametinib 1 mg QD Dosing of first patient in Erasca’s pivotal Phase 3 tria
Read more →ERASErasca Presents Promising Initial Phase 1b Dose Escalation Data from FLAGSHP-1 for ERAS-601 Plus Cetuximab in Patients with Advanced Solid Tumors at the 2023 AACR Annual Meeting
ERAS-601, a potential best-in-class SHP2 inhibitor, blocks oncogenic signal transduction to delay onset of therapeutic resistance Combination was well-tolerated; supports ‘three weeks on, one week off’ dosing of ERAS-601 Dose expansion data in HPV-negative HNSCC expected in H1
Read more →ERAS▼ -8.8%on this news
Erasca Strengthens Clinical and Regulatory Leadership with Two Key Appointments as Company Transitions to Late-Stage Development
Shannon R. Morris, M.D., Ph.D., promoted to Chief Medical Officer Chandra D. Lovejoy promoted to Chief Regulatory Affairs Officer SAN DIEGO, April 10, 2023 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discove
Read more →ERASErasca Reports Fourth Quarter 2022 and Full Year 2022 Financial Results and Business Updates Signed exclusive worldwide license for pan-RAF inhibitor naporafenib and completed concurrent $100 million equity offering Mult
Erasca, Inc. reported its fourth quarter and full year 2022 financial results, highlighting significant milestones including the exclusive license agreement for pan-RAF inhibitor naporafenib and a $100 million equity offering. The company is set to announce several important clinical data readouts throughout 2023, focusing on therapies for RAS/MAPK pathway-driven cancers. With a strong cash position, Erasca aims to advance multiple clinical trials, including SEACRAFT-1 for naporafenib in solid tumors and various trials for its other pipeline products.
Read more →ERASErasca Announces Poster Presentation at the 2023 AACR Annual Meeting
SAN DIEGO, March 14, 2023 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced the company will
Read more →ERASAnticipated key milestones - Updated
The article outlines the anticipated key milestones for ERAS in their clinical trial programs, notably mentioning the timelines for various trials in 2023 and 2024. The SEACRAFT and HERKULES programs aim to explore treatments for different types of solid tumors and melanoma. Notable trials include ERAS-007 and ERAS-601, which are set to provide preliminary data on the safety and effectiveness of novel combination therapies. The focus on CNS-penetrant therapies indicates a targeted approach to challenging cancers such as glioblastoma multifome.
Read more →ERASErasca to Present at the Guggenheim Oncology Conference 2023
SAN DIEGO, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation
Read more →ERASErasca to Present at the 41st Annual J.P. Morgan Healthcare Conference
SAN DIEGO, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation
Read more →ERASErasca Announces First Patient Dosed in HERKULES-1 Phase 1b Trial Evaluating ERAS-007 and ERAS-601 MAPKlamp Combination in RAS/MAPK Pathway-Altered Solid Tumors
Promising preliminary monotherapy data for ERK1/2 inhibitor ERAS-007 and SHP2 inhibitor ERAS-601 in advanced solid tumors, which had favorable safety, tolerability, and efficacy profiles that support combination development BRAF Class 2 and 3 alterations have no approved targete
Read more →ERASErasca Announces FDA Clearance of IND Application for CNS-Penetrant KRAS G12C Inhibitor ERAS-3490 in KRAS G12C-Mutated Advanced or Metastatic Solid Tumors
SAN DIEGO, Dec. 13, 2022 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced the United States
Read more →ERAS▼ -22.3%on this news· ran to -34% by day 3shared move
On a Journey to Erase Cancer Erasca Corporate Presentation December 2022 Disclaimer: Forward Looking Statements & Market Data We caution you that this presentation contains forward-looking statements. All statements othe
Disclaimer: Forward Looking Statements & Market Data We caution you that this presentation contains forward-looking statements. All statements other than statements of historical facts contained in this presentation, including statements regarding the anticipated naporafenib lic
Read more →ERAS▼ -22.3%on this news· ran to -34% by day 3shared move
Erasca Announces Exclusive Worldwide License for Pan-RAF Inhibitor Naporafenib
Concurrent $100 million equity offering Naporafenib has a potential first-in-class and best-in-class profile in multiple RAS/MAPK pathway-driven tumors Pivotal-ready asset has been dosed in over 500 patients to date and expands Erasca’s addressable population Erasca to host co
Read more →ERAS▲ +6.3%on this news
Erasca Announces Clinical Trial Collaboration and Supply Agreement with Pierre Fabre to Evaluate ERAS-007 and Encorafenib Combination
ERAS-007, a potential best-in-class ERK1/2 inhibitor, is being evaluated in combination with encorafenib and cetuximab in BRAF V600E-mutant metastatic colorectal cancer Erasca previously signed CTCSAs with Pfizer and Eli Lilly to evaluate encorafenib and cetuximab in combination
Read more →ERASErasca Reports Third Quarter 2022 Financial Results and Business Updates Positive preliminary monotherapy data for ERAS-007 and ERAS-601 support ongoing and future combination trials Signed CTCSAs with Eli Lilly to suppl
Erasca Reports Third Quarter 2022 Financial Results and Business Updates Positive preliminary monotherapy data for ERAS-007 and ERAS-601 support ongoing and future combination trials Signed CTCSAs with Eli Lilly to supply cetuximab in combination with ERAS-601 and with Pfizer t
Read more →ERASErasca Announces Clinical Trial Collaboration and Supply Agreement with Pfizer to Evaluate ERAS-007 and Palbociclib Combination
ERAS-007, a potential best-in-class ERK1/2 inhibitor, is being evaluated in combination with palbociclib in patients with KRAS- and NRAS-mutant colorectal cancer and KRAS-mutant pancreatic cancer Erasca previously signed CTCSAs with Pfizer and Lilly to evaluate ERAS-007 in combi
Read more →ERASErasca Announces Four Poster Presentations at the Upcoming 34th EORTC-NCI-AACR Symposium
Initial Phase 1/1b patient data for ERK1/2 inhibitor ERAS-007 and SHP2 inhibitor ERAS-601 in advanced solid tumors show safe and tolerable profiles for combination development CNS-penetrant EGFR inhibitor ERAS-801 demonstrates superior anti-tumor activity over osimertinib in pre
Read more →ERASErasca to Present at the Bank of America Securities Precision Oncology Conference 2022
SAN DIEGO, Sept. 26, 2022 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation
Read more →ERASErasca to Present at the Morgan Stanley Global Healthcare Conference
SAN DIEGO, Sept. 09, 2022 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation
Read more →ERAS▲ +6.2%on this newsshared move
Erasca Presents Promising Preliminary Phase 1/1b Monotherapy Data for ERAS-007 ERK and ERAS-601 SHP2 Inhibitors Supporting Ongoing and Future Combination Trials
23% (6/26) of patients with RAS/MAPK-altered non-CRC solid tumors and 44% (4/9) with BRAF-driven non-CRC solid tumors responded (confirmed and unconfirmed PR) to single agent ERAS-007 or ERAS-601 ERAS-007 and ERAS-601 had favorable safety and tolerability profiles with largely n
Read more →ERASErasca to Host R&D Day with KOL Dr. David Hong on Lead Clinical Programs ERAS-007 and ERAS-601 in Advanced Solid Tumors
Virtual event on Wednesday, September 7 at 4:30 PM ET will feature key opinion leader (KOL) David Hong, M.D., from MD Anderson Cancer Center Company to present preliminary clinical data and future directions for its lead clinical candidates with best-in-class potential, ERK1/2 i
Read more →ERAS▲ +5.1%on this newsshared move
Erasca and MD Anderson Announce Strategic Research and Development Collaboration in RAS/MAPK-Driven Cancers
Initial focus of five-year collaboration will be on potentially best-in-class ERK1/2 inhibitor ERAS-007 and SHP2 inhibitor ERAS-601, which together comprise Erasca’s first MAPKlamp combination Additional Erasca programs, including KRAS G12D inhibitor ERAS-4, also will be investi
Read more →ERAS▼ -11.1%on this news
Erasca Reports Second Quarter 2022 Financial Results and Business Updates Initial Phase 1b monotherapy data for ERAS-007 in HERKULES-1 and first-in-human Phase 1 monotherapy data for ERAS-601 in FLAGSHP-1 expected in H2
Erasca Reports Second Quarter 2022 Financial Results and Business Updates Initial Phase 1b monotherapy data for ERAS-007 in HERKULES-1 and first-in-human Phase 1 monotherapy data for ERAS-601 in FLAGSHP-1 expected in H2 2022 IND filing for CNS-penetrant KRAS G12C inhibitor ERAS
Read more →ERASErasca Announces Clinical Trial Collaboration and Supply Agreement with Eli Lilly and Company to Evaluate ERAS-601 and Cetuximab Combination
ERAS-601, a potential best-in-class SHP2 inhibitor, is being investigated alone and in combination in the ongoing FLAGSHP-1 Phase 1/1b trial Erasca previously signed CTCSAs with Lilly and Pfizer to evaluate cetuximab and encorafenib in combination with ERK1/2 inhibitor ERAS-007
Read more →ERAS▲ +13.2%on this news
Erasca to Present at the 2022 Jefferies Healthcare Conference
SAN DIEGO, June 03, 2022 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation
Read more →ERASErasca Announces Trial to Evaluate ERAS-007 in Combination with KRAS G12C Inhibitor in KRAS-Driven Cancers
SAN DIEGO, June 02, 2022 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced a trial to investi
Read more →ERASErasca Strengthens Clinical and Commercial Leadership with Three Key Appointments
Shannon Morris, M.D., Ph.D., appointed as Senior Vice President of Clinical Development Amy Grekowicz Parker appointed as Vice President of Clinical Operations John Lo, Ph.D., appointed as Senior Commercial Advisor and member of Erasca’s newly expanded Research, Development, an
Read more →ERASErasca Reports First Quarter 2022 Financial Results and Business Updates Presented compelling preclinical data at 2022 AACR Annual Meeting supporting clinical development of potentially best-in-class programs Initial Pha
Erasca Reports First Quarter 2022 Financial Results and Business Updates Presented compelling preclinical data at 2022 AACR Annual Meeting supporting clinical development of potentially best-in-class programs Initial Phase 1b monotherapy data for ERAS-007 and Phase 1 monotherap
Read more →ERASErasca to Present at the Bank of America Securities 2022 Healthcare Conference
SAN DIEGO, May 03, 2022 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation i
Read more →ERASErasca Appoints Jean Liu to its Board of Directors
SAN DIEGO, April 27, 2022 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced the appointment o
Read more →ERASErasca Presents Compelling Preclinical Data Supporting Clinical Development of Potentially Best-In-Class Programs ERAS-007, ERAS-601, and ERAS-3490 at 2022 AACR Annual Meeting
ERAS-007 is a potent and selective small molecule ERK1/2 inhibitor with long target residence time, which promotes sustained RAS/MAPK pathway inhibition ERAS-601 is a potent and selective small molecule SHP2 inhibitor with broad anti-tumor activity that blocks oncogenic signal t
Read more →ERASErasca To Host Investor Event with Leading KOL Dr. Scott Kopetz on Therapeutic Opportunities in Cancers Driven by the RAS/MAPK Pathway
Virtual event on Tuesday, April 12 at 4:30 PM ET will feature key opinion leader (KOL) Scott Kopetz, M.D., Ph.D., from MD Anderson Cancer Center Company and KOL to discuss an overview of unmet medical needs and therapeutic opportunities in cancers driven by the RAS/MAPK pathway,
Read more →ERASErasca Reports Fourth Quarter 2021 Financial Results and Business Updates Five ongoing clinical trials evaluating candidates ERAS-007 (ERKi), ERAS-601 (SHP2i), and ERAS-801 (CNS-penetrant EGFRi) Initial Phase 1b data for
Erasca Reports Fourth Quarter 2021 Financial Results and Business Updates Five ongoing clinical trials evaluating candidates ERAS-007 (ERKi), ERAS-601 (SHP2i), and ERAS-801 (CNS-penetrant EGFRi) Initial Phase 1b data for HERKULES-1 and Phase 1 data for FLAGSHP-1 expected in H2
Read more →ERASErasca Announces Clinical Trial Collaboration and Supply Agreement with Eli Lilly and Company to Evaluate ERAS-007 and Cetuximab Combination
ERAS-007, a potential best-in-class ERK1/2 inhibitor, is being evaluated clinically in combination with encorafenib and cetuximab in patients with BRAF V600E-mutant mCRC Erasca previously signed a clinical trial collaboration and supply agreement with Pfizer for encorafenib for
Read more →ERASErasca Announces Six Poster Presentations at the 2022 AACR Annual Meeting
SAN DIEGO, March 08, 2022 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced the company will
Read more →ERASErasca to Present at the Guggenheim Healthcare Talks 2022 Oncology Day
SAN DIEGO, Feb. 03, 2022 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation
Read more →ERAS▼ -6%on this news
Erasca Strengthens Leadership Team with Two Key Executive Appointments
Lisa Tesvich-Bonora appointed as Chief People Officer Robert Shoemaker promoted to Senior Vice President of Research SAN DIEGO, Jan. 18, 2022 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developi
Read more →ERASErasca to Present at the 40th Annual J.P. Morgan Healthcare Conference
SAN DIEGO, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation
Read more →ERASErasca Announces FDA Clearance of IND Application for ERAS-801 in Glioblastoma Multiforme and Collaboration with GCAR for Potential Inclusion in GBM AGILE Clinical Trial
IND filing achieved ahead of schedule; dosing of first patient in THUNDERBBOLT-1 Phase 1 clinical trial in recurrent GBM anticipated in Q1 2022 Early collaboration with GCAR could support potential registrational path in GBM ERAS-801 is a highly CNS-penetrant EGFR inhibitor wit
Read more →ERASErasca Added to the Nasdaq Biotechnology Index
SAN DIEGO, Dec. 14, 2021 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that the company h
Read more →ERASErasca to Present at the Evercore ISI 4th Annual HealthCONx Conference
SAN DIEGO, Nov. 16, 2021 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation
Read more →ERASErasca Reports Third Quarter 2021 Financial Results and Business Updates Strong execution leading to four ongoing clinical trials evaluating lead candidates ERAS-007 (ERKi) and ERAS-601 (SHP2i) Named one of Fierce Biotec
Erasca Reports Third Quarter 2021 Financial Results and Business Updates Strong execution leading to four ongoing clinical trials evaluating lead candidates ERAS-007 (ERKi) and ERAS-601 (SHP2i) Named one of Fierce Biotech's Fierce 15 most promising biotechnology companies of 20
Read more →ERASErasca Announces Presentation of Preclinical Data on ERAS-801, a CNS-Penetrant EGFR Inhibitor with Broad Activity against Oncogenic EGFR Alterations, at AACR Conference on Brain Cancer
ERAS-801's CNS penetration: four times higher than approved EGFR inhibitors Comprehensive inhibition against oncogenic EGFR vIII and wildtype alterations Improved outcomes in over 90% of EGFR-driven patient-derived glioblastoma models IND submission in refractory glioblastoma
Read more →ERAS▲ +5.6%on this news
Erasca is Named One of Fierce Biotech’s “Fierce 15” Biotechnology Companies of 2021
SAN DIEGO, Sept. 27, 2021 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that Fierce Biote
Read more →ERASErasca Announces First Patient Dosed in HERKULES-3, a Phase 1b/2 Gastrointestinal Cancer Master Protocol Evaluating ERAS-007 in Multiple Combinations
SAN DIEGO, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced dosing of the fir
Read more →ERASErasca Announces First Patient Dosed in HERKULES-2 Phase 1b/2 Lung Cancer Master Protocol Evaluating ERAS-007 in Multiple Combinations
SAN DIEGO, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced dosing of the fir
Read more →ERAS▼ -10.8%on this newsshared move
Erasca Announces Clinical Trial Collaboration and Supply Agreement with Pfizer to Evaluate ERAS-007 and Encorafenib Combination
ERAS-007, a potential best-in-class ERK1/2 inhibitor, will be evaluated in combination with encorafenib and cetuximab in patients with BRAF V600E-mutant metastatic colorectal cancer (mCRC) HERKULES-3 CRC Phase 1b/2 trial initiation expected in H2 2021 SAN DIEGO, Sept. 08, 2021
Read more →ERAS▲ +6.5%on this newsshared move
Erasca to Participate in the Morgan Stanley 19th Annual Global Healthcare Virtual Conference
SAN DIEGO, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation
Read more →ERASErasca Reports Second Quarter 2021 Financial Results and Business Updates Successfully closed $345 million upsized IPO in July 2021 On track to initiate multiple HERKULES Phase 1b/2 trials in 2021 with data readout(s) be
Erasca Reports Second Quarter 2021 Financial Results and Business Updates Successfully closed $345 million upsized IPO in July 2021 On track to initiate multiple HERKULES Phase 1b/2 trials in 2021 with data readout(s) beginning in 2022 Strengthened executive leadership team wi
Read more →ERAS▲ +7.3%on this news
Erasca Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
SAN DIEGO, July 20, 2021 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced the closing of its
Read more →ERASErasca Announces Pricing of Upsized Initial Public Offering
SAN DIEGO, July 15, 2021 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced the pricing of its
Read more →Competitive Position
How ERAS ranks across every disease it competes inCompetitive Position is a premium feature
See how ERAS ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial